about
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patientPrevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasmsSymptoms of posttraumatic stress disorder in patients who have had a myocardial infarctionA new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysisAdaptor protein Lnk binds to and inhibits normal and leukemic FLT3.Protein Z and its role in venous and arterial thrombosis.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmSH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.Myeloid sarcoma: current approach and therapeutic options.Monitoring response to osteoporosis therapy with alendronate by a multisite ultrasound device: a prospective study.Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study.Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study.The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.Protein Z levels and central retinal vein or artery occlusion.
P50
Q21090134-1A352E33-5BF4-486A-89B3-979F404E852BQ24595117-79E99603-7FEB-4910-895B-23E465FAE8B8Q28217780-0EF150D3-47B7-4C65-BD45-D564E097C706Q33294184-C934DF3C-E24E-41AD-A214-5286BFDF9488Q33390350-5043D2C2-8BB7-4548-8A75-D0FB21F5EAA6Q33418153-5D139D46-0F74-4B51-A5E6-789DCD361470Q33425801-CBC65B39-3785-4E36-83BB-9C2012B5BA9DQ34592058-7609AF52-8166-4420-998C-887724DF4EB9Q34956540-198781E0-AD06-448C-9C45-E3439315946FQ35783433-83BC7E64-4C49-44B1-8943-07CA34C38E21Q36333540-150DD474-5DAC-4CA5-8C27-24526C90D599Q36383644-4EA7FE07-24A6-4111-A460-775059233251Q36612569-D9D36790-13C5-4471-A0F9-BC159117CD30Q36901651-A6CE538A-D9BC-4648-8C2F-C0FB2A3297C0Q38095960-946CCE44-151D-4F8F-9B06-884AD1B2C790Q38519362-B8308EF7-51AE-4492-8DB3-8A4EB57EBD2DQ39026569-ACCC77AA-D409-443F-9017-4A48D0B893BDQ40078967-02109449-4029-48EC-8D4A-E1A586F14644Q40544279-F5387DFC-CC54-4654-8CE5-5EF3289CF8CAQ42651953-08790D6A-6A9F-462F-B2A5-8B2BC59FE96DQ44888762-05F66860-C627-4EC7-AEAE-C4E76AE90A67Q45858841-23385140-84EA-480A-BF44-91DD2DE2B997Q46726019-8618875E-EA85-49CD-817F-27AFA2DD1537
P50
name
Maya Koren-Michowitz
@ast
Maya Koren-Michowitz
@en
Maya Koren-Michowitz
@es
Maya Koren-Michowitz
@nl
type
label
Maya Koren-Michowitz
@ast
Maya Koren-Michowitz
@en
Maya Koren-Michowitz
@es
Maya Koren-Michowitz
@nl
prefLabel
Maya Koren-Michowitz
@ast
Maya Koren-Michowitz
@en
Maya Koren-Michowitz
@es
Maya Koren-Michowitz
@nl